Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nevis Brands Inc C.NEVI

Alternate Symbol(s):  NEVIF

Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent cannabis experience with no cannabis taste or smell. Major offers various flavors, such as volcanic orange mango, sunset pink lemonade, pacific coast blue raspberry, dreamin' of passion, and sacred grape. It also offers Major Minis, which is a smaller 2 ounce (oz) shot. Major Minis comes in three flavors, such as blueberry, fruit punch, and blackberry lemonade.


CSE:NEVI - Post by User

Bullboard Posts
Post by EarlyInvestor59on Mar 10, 2018 6:05pm
148 Views
Post# 27697820

Bakers N Brothers

Bakers N Brothers

Is a huge funds in USA that invest a good  chunk in Health Care sectore. In their last Q&A, they said to be looking at canadian medical research company... more precisely, they said to aims aquiring stakes in company doing EXACTLY what PAS is doing.
 

I think this kind of market sentiment confirm further more the interest from the Pharma and Institutionnal sector.
 

Remember guy. Biochem Pharma went from 20 millions to 4 billions wihtout minimal or no sales. The product of the research itself was the value. I think we have a much smaller (in term of final value) but still ultra potential company here. The team behind the company and the nature of the findings justify 1.50$/2$ per share in the very short term imho.

 

Have a great days
 

Best regards

Bullboard Posts